Daiichi Sankyo Announces 5-year Business Plan (FY 2016 – FY 2020)

TOKYO, Japan (March 31, 2016) - Daiichi Sankyo Company, Limited today announced its 5-year Business Plan for fiscal 2016 - 2020 (hereafter, 5YBP).

1. 2025 Vision
Daiichi Sankyo Group aspires to be a “Global Pharma Innovator with Competitive Advantage in Oncology” as its 2025 Vision by positioning its innovative pharmaceutical business, centered on oncology, as a core business in order to become a global company developing and marketing innovative products for diseases with unmet needs to change standard of care. The main goals of the 2025 Vision are as follows:
- To have specialty area*1 business centered on oncology business as the core business
- To have enriched regional value products*2 aligned with regional market
- To have innovative products and pipeline changing SOC*3
- To realize shareholders’ value through highly efficient management

*1 Specialty area: Drugs mainly prescribed at hospital and/or by specialty practitioners
*2 Regional value products: Products aligned with regional market
*3 SOC: Standard of Care

2. Outline of the 5YBP
The following two management issues are addressed within the plan to provide a basis for realizing our 2025 Vision.

<Challenge 1> Grow beyond FY2017 LOE
To overcome the patent cliff of the antihypertensive “Olmesartan,” one of our main products, we will make efforts for revenue recovery and profit generation, aiming at a revenue of 940 billion JPY and an operating profit of 100 billion JPY in FY 2017.
- **Measures of revenue recovery**
  Accelerate the marketing of the anticoagulant “edoxaban” and major products in Japan, and Luitpold business.

- **Measures of profit generation**
  Profit generation through cost reduction and streamlining

**<Challenge 2> Establish Foundation of Sustainable Growth**
To establish a basis for sustainable growth, we developed the following business strategy, investment policy for future growth and shareholder returns policies in order to achieve the targets in FY 2020.

**- Targets in FY 2020**

<table>
<thead>
<tr>
<th>Numerical goals</th>
<th>FY 2015 (Forecast)</th>
<th>FY 2017 (Target)</th>
<th>FY 2020 (Target)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>980</td>
<td>940</td>
<td>1,100</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>130</td>
<td>100</td>
<td>165</td>
</tr>
</tbody>
</table>

Assumption: Exchange rate of 1 USD = 120 JPY; 1 EUR = 130 JPY

**Increase value of late-stage pipeline**
3 to 5 products launched within the next five years with peak-sales of more than 100 billion JPY each

**ROE: 8% or more (FY 2020)**

**- Business Strategies**
Strategy 1: Grow Edoxaban with a revenue of 120 billion JPY or more
Strategy 2: Establish Oncology Business with a revenue of 40 billion JPY or more
Strategy 3: <Japan> Grow as No.1 company in Japan
Strategy 4: <US> Expand US Businesses
- Pain Franchise: Revenue of 100 billion JPY or more
- Luitpold: Revenue of 150 billion JPY
Strategy 5: Continuously Generate Innovative Medicine Changing SOC
- Create new drugs in Oncology/New Horizon area
- Realize clinical application of innovative technology
Strategy 6: Enhance Profit Generation

**- Investments for future growth and shareholder returns**
Aimed at enhancing shareholder returns, while giving priority to investments of future growth

**- Investment for Future Growth:** Allocate investments according to the above strategies 1-5, with the highest priority to oncology field
- Shareholder Returns (during 5YBP):
  Total return ratio*: 100% or more
  Annual ordinary dividends: more than 70 JPY
  Flexible acquisition of own shares

*The total shareholder return ratio(dividends + total acquisition costs of own shares) / profit attributable to owners of the company may be different from the numbers Daiichi Sankyo forecasts due to factors involving strategic investments, including R&D costs and business development investments, material changes of the business environment surrounding Daiichi Sankyo or business performance of Daiichi Sankyo, legal or compliance issues such as insider trading regulations, or other facts or circumstances. The increase of cash flow related to the total shareholder return ratio may not be realized as expected in this material due to a variety of circumstances, such as the market penetration of generic drugs, delay or cancelation of approvals for new drugs, payment of damages or compensation in connection with litigation or other legal proceedings.

*For details, please refer to the attached documents.
5-Year Business Plan
(FY2016 - FY2020)

DAIICHI SANKYO CO., LTD

Joji Nakayama
President and CEO

March 31, 2016
Forward-Looking Statements

Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward looking statements were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from Daiichi Sankyo’s outlook or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward.

Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material, but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof.

The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain.

This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere.

This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion.

Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.
Agenda

- Review of the past
- External Environment
- 2025 Vision
- 5-Year Business Plan (5YBP)
  - Challenge 1: Grow beyond FY2017 LOE
  - Challenge 2: Establish Foundation of Sustainable Growth
  - Conclusion
Our Mission
To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs

Vision
To become a Global Pharma Innovator

1st MTP* (2007-09)
Maximization of synergy and expansion of growth foundation
- Focus on thrombosis, cancer, diabetes, and other fields
- Maximize sales of Olmesartan franchise
- Acquired Ranbaxy into Group in 2008

2nd MTP (2010-12)
Advancement of Global Hybrid Business Model
- Focus on thrombosis, CV-M, and cancer fields
- Expand operating foundations in Japan
- Conduct frontline and backyard collaboration with Ranbaxy

3rd MTP (2013-15)
Promotion of measures toward Sustainable Growth beyond LOE
- Focus on thrombosis, CV-M, and cancer fields
- Divest and liquidate Ranbaxy over period from April 2014–April 2015
- Return to innovative business

*MTP: Mid-term plan
Review of the Past

Performance trend

* Ranbaxy figures are Excluded
* Up to FY2011: J-GAAP, From 2012: IFRS

- Maximize OLM franchise ★★★
- Establish Thrombosis franchise ★★
- Launch Oncology business ★
- Expand JP business ★★★
- Create global top class pipeline ★
- Establish industry best operational efficiency ★★
- Realize global hybrid business

FY2015 (Forecast)
Revenue
980.0 Bn JPY
Operating Profit
130.0 Bn JPY

1st MTP
2nd MTP
3rd MTP
Change of Strategy
External Environment

- Rising pressure for healthcare cost containment, emphasis on cost effectiveness, and influence of Payer
- Growing market for drugs prescribed at hospitals and by specialists (specialty area drugs such as those for cancer and other serious illnesses)
- Significant opportunities for innovative medicine changing standard of care (SOC)
- Intensified competition for acquiring promising products and pipeline
- Differences in market share of drugs by country and region due to differences in regulatory and insurance systems

- **Japan**
  Stagnant market growth expected due to worsening national finances (80% target for generics, recalculation of market growth projections, etc.) while advancement of policy to encourage innovation (promotion of regenerative medicine and cell therapy advancement, new drug discovery incentives, etc.)

- **US**
  Stable growth expected for world’s No. 1 market, home to cutting-edge science born out of intense competition

- **EU**
  Low-growth market presenting opportunities for pharmaceuticals that have been highly evaluated for cost effectiveness

- **China**
  Continual growth as world’s No. 2 market, but sense of uncertainty rising recently
2025 Vision

Global Pharma Innovator with Competitive Advantage in Oncology

◆ To have Specialty area* business centered on Oncology business as the core business
◆ To have enriched regional value products** aligned with regional market
◆ To have innovative products and pipeline changing SOC***
◆ To realize shareholders’ value through highly efficient management

*Specialty area: Drugs mainly prescribed at Hospital and/or by Specialty practitioners
**regional value products: Products aligned with regional market
***SOC: Standard of Care
Management Policy Transformation

2016-2020
5-Year Business Plan

Transformation toward 2025 Vision

Until 2015

- CVM area
- PCP focus
- Global products
- In-house
- Sales volume

2025 Vision

- Oncology area
- Specialty area
- Regional value
- Alliance
- Sustainable profit growth
5-Year Business Plan
(FY2016 - FY2020)

DS Transformation — A Bridge to Tomorrow
5-Year Business Plan (5YBP)

◆ Challenge 1: Grow beyond FY2017 LOE
  ➢ Measures of Revenue Recovery
  ➢ Measures of Profit Generation

◆ Challenge 2: Establish Foundation of Sustainable Growth
  ➢ FY2020 Targets and Business Strategy
  ➢ Investment for Future Growth and Shareholder Returns
  ➢ CSR and Corporate Governance

◆ Conclusion
Challenge 1: Grow beyond FY2017 LOE

- Measures of revenue recovery
  - Growth of Edoxaban
  - Growth of Japan Business
  - Growth of Luitpold Business

- Measures of profit generation
Measure 1: Growth of Edoxaban
Steady Growth of Market Share in Japan

Market share grew by 7.5 points in one year and reached 13.1%
Smooth Launch in Germany

Start is better than that of Product A which is now at the No.2 position in Germany.

Germany: Monthly IMS sales for 5 months from launch in SPAF

©2016 IMSHealth
Calculated based on IMS MIDAS Sales Data: 2015 Dec.
Reprinted with permission
Accelerate Growth in Japan and Europe

Appeal unique product profile

- **Product profile**
  - The only once-diaily DOAC that offers superiority to warfarin with less major bleeding in non-valvular atrial fibrillation and with less clinically relevant bleeding in DVT/PE
  - Dosing optimization per patients’ condition
  - Evidence backed by the largest single comparative studies in NVAF and VTE with very high quality

Strategies in Japan and Europe

- **Japan**
  - The only domestically manufactured DOAC with 3 indications
  - Sales capabilities with high quality

- **Europe**
  - Steady launch in major countries
  - Further promote access models in line with market needs in each country

Conservative assumption that insurance reimbursement status in United States will remain unchanged
Measure 2: Growth of Japan Business
Grow Major Products in Japan

Quickly maximize major product sales by leveraging high quality sales capabilities

Product strategies

- **Nexium (anti-ulcer: Proton Pump Inhibitor)**
  Maintain No. 1 share by establishing position as “first choice” drug for GERD* treatment

- **Memory (treatment for Alzheimer’s Disease)**
  Standardize combination therapy with ChE** inhibitor for the treatment of moderate-to-severe AD*** by provision of clinical evidence

- **Pralia (treatment for osteoporosis)**
  Accelerate market penetration by promoting high evaluation received by guidelines

- **Ranmark (treatment for bone metastasis)**
  Maintain position as standard of care for treating bone metastasis of cancer

- **Efient (antiplatelet)**
  Acquire dominating No. 1 share in heart area by promoting dosage ideal for Japanese

- **Teneria (treatment for type 2 diabetes)**
  Appeal efficacy and ease of use for elderly people and patients with renal impairment to aim for first-line treatment for diabetes

*GERD: Gastroesophageal Reflux Disease
**ChE: Cholinesterase
***AD: Alzheimer's disease

Total of 6 products in right column (excl. Lixiana), excluding the impact of mandated price revisions
Measure 3: Growth of Luitpold Business
Growing US IV Iron Market

Injectafer drives the IV Iron Market growth of 13.6% in $ and 6.4% in gram volume.

IV Iron $ sales (includes dialysis)

<table>
<thead>
<tr>
<th>Year</th>
<th>$ Million</th>
<th>% of Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAT Jan 2014</td>
<td>509.8</td>
<td>1%</td>
</tr>
<tr>
<td>MAT Jan 2015</td>
<td>591.1</td>
<td>17%</td>
</tr>
<tr>
<td>MAT Jan 2016</td>
<td>671.6</td>
<td>21%</td>
</tr>
</tbody>
</table>

IV Iron kg sales (includes dialysis)

<table>
<thead>
<tr>
<th>Year</th>
<th>kg</th>
<th>% of Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAT Jan 2014</td>
<td>1,774</td>
<td>7%</td>
</tr>
<tr>
<td>MAT Jan 2015</td>
<td>1,919</td>
<td>13%</td>
</tr>
<tr>
<td>MAT Jan 2016</td>
<td>2,042</td>
<td>9%</td>
</tr>
</tbody>
</table>

Source: IMS National Sales Perspectives Jan 2016 (includes all US IV Iron sales in all channels including dialysis chains).
Accelerated Growth of Injectafer and Generic Injectable

Become **1 Bn USD** company in FY2017

**IRON FRANCHISE**

- **Market:** 665 Mn USD in sales (2015) with consistent growth trends (>10%)
- **Accelerate Injectafer Growth (CAGR 20-30%)**
  - Differentiate from other i.v. irons
  - Expand Sales team coverage to Gastro, Oncologist, Nephrologist
  - Become Market share leader in non-dialysis segment
  - Raise awareness of IDA among physicians & patients
  - Roll out new patient centric campaign

**GENERIC INJECTABLE FRANCHISE**

- **Market:** 22.8 Bn USD in sales (2015) with consistent growth trends
- **Maximize / expand existing portfolio**
  - Reintroduce historical products*
  - Expedite Commercial Launches
  - Respond to rapid market change

*Historical products: Luitpold manufactured and sold in the past
Accelerate growth of main products

- Growth of Edoxaban
- Growth of Japan Business
- Growth of Luitpold Business

Measures of Revenue Recovery

FY2015 (Forecast)
Revenue 980.0 Bn JPY

- Decrease revenue due to patent cliff and NHI price cut in Japan

FY2017 (Target)
Revenue 940.0 Bn JPY
Measures of Profit Generation

Major measures conducted by FY2015

- Restructuring in Europe (FY2014)
- Restructuring in Japan (FY2014)
- Sale of Akita plant (FY2014)
- Restructuring in US (FY2015)
- Restructuring in R&D (FY2015)

The impact of above measures will be realized as cost reduction effect during 5YBP
Measures of Profit Generation

- Impact of cost reduction measures conducted by FY2015
- Cost reduction impacts in FY2016 & FY2017
  
  Realization of Process Excellence
  - Further cost reductions and streamlining
  - Optimization of manufacturing systems globally
  - Further enhancement of procurement

FY2015 (Forecast)
Operating Profit
130.0 Bn JPY

- Increase in gross profit by growth of products
- Decrease in profit due to patent cliff and NHI price cut in Japan

FY2017 (Target)
Operating Profit
100.0 Bn JPY

Cost reduction impacts in FY2016 & FY2017

+57.0 Bn JPY
◆ Challenge 1: Grow beyond FY2017 LOE
  ➢ Measures of Revenue Recovery
  ➢ Measures of Profit Generation

◆ Challenge 2: Establish Foundation of Sustainable Growth
  ➢ FY2020 Targets and Business Strategy
  ➢ Investment for Future Growth and Shareholder Returns
  ➢ CSR and Corporate Governance

◆ Conclusion
## FY2020 Targets

<table>
<thead>
<tr>
<th></th>
<th>FY2015 (Forecast)</th>
<th>FY2017 (Target)</th>
<th>FY2020 (Target)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue (Bn JPY)</strong></td>
<td>980.0</td>
<td>940.0</td>
<td>1,100.0</td>
</tr>
<tr>
<td><strong>Operating Profit (Bn JPY)</strong></td>
<td>130.0</td>
<td>100.0</td>
<td>165.0</td>
</tr>
</tbody>
</table>

- **Increase value of late-stage pipeline**
  3 - 5 products launched within the next 5 years with peak-sales of more than 100.0 Bn JPY each

Assumption: Exchange rate of 1USD=120JPY, 1EUR=130JPY
Business Strategy

<Global Products>
◆ Strategy 1 : Grow Edoxaban
◆ Strategy 2 : Establish Oncology Business

<Regional Value Products>
◆ Strategy 3 : <JP> Grow as No.1 company in Japan
◆ Strategy 4 : <US> Expand US Businesses

<Value for Pipeline>
◆ Strategy 5 : Continuously Generate Innovative Medicine Changing SOC

<Highly Efficient Management>
◆ Strategy 6 : Enhance Profit Generation
Global Products
Strategy 1
Grow Edoxaban
Growth of Global DOAC* Market

**DOAC market trend**

**VKAs vs. DOACs - Volume (DOT)**

*DOAC: Direct Oral Anticoagulant  Same meaning as NOAC (novel oral anticoagulant)*

©2016 IMSHealth
Calculated based on IMS MIDAS Sales Data 2011-2015
Reprinted with permission
Expand as Growth Driver for Mid to Long Term

Global strategies

- Execute launch strategy
- Appeal product profile continuously
- Generate new evidence to strengthen product
  - Ensure-AF, Hokusai-VTE Cancer etc.
  - ENTA Registries

Regional strategies

- Japan
  - Utilize product profile and fine-tuned sales capabilities with high quality
  - Nurture into Japan’s No. 1 DOAC
- Europe
  - Conduct promotion across Europe through collaboration with MSD*
- US
  - Acquire prescriptions through specifically targeted promotions
  - Improve market access
- ASCA and other regions
  - Realize early approval and launch in all countries of operation
  - Conduct promotion through collaboration with best partners

*MSD: Merck Sharp and Dohme Europe Subsidiary of Merck & Co., Inc.

Conservative assumption that insurance reimbursement status in United States will remain unchanged

Over 120.0 Bn JPY (1 Bn USD) in FY2020

<table>
<thead>
<tr>
<th>Year</th>
<th>Others</th>
<th>Japan/Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2015</td>
<td>14.7</td>
<td></td>
</tr>
<tr>
<td>FY2017</td>
<td></td>
<td>69.0</td>
</tr>
<tr>
<td>FY2020</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Grow sales with the expanding DOAC market (image)

- **Launch Strategy (2015-2017)**: Launch in major countries
- **DOAC market**
- **Edoxaban**
- **New Evidence (2018-2020)**: Maximize brand value
- **Sustainable Growth (2021-)**

Global Products

Strategy 2
Establish Oncology Business
Establish Oncology Business

- Establish oncology business by launching current late-stage pipeline
- Steadily drive development of early-stage pipeline
- Enrich pipeline by acquisition of external assets
- Accelerate oncology R&D by new R&D organization

Revenue
FY2020: over **40.0 Bn JPY**
FY2025: approx. **300.0 Bn JPY**
Oncology Business Expansion

Late-stage development
- TLR
- NDA
- Approval
- Approx. 300.0 Bn JPY

Early-stage development
- Pre-clinical
- Approval
- Contribution to Revenue
- Approx. 40.0 Bn JPY

New in-license
- Innovative technology etc.
- • DS-8201
- • DS-3201
- • DS-3032
- • DS-6051

Late-stage development
- • quizartinib
- • tivantinib
- • pexidartinib
- • patritumab

Early-stage development
- • vemurafenib
- • denosumab
Establish Oncology Business by Launching Current Late-stage Pipeline

**Contribute to 40.0 Bn JPY in Revenue with 4 products in FY2020**

<table>
<thead>
<tr>
<th>Product</th>
<th>Expectation</th>
<th>Indications</th>
<th>Regulatory Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quizartinib</td>
<td>~100.0 Bn JPY</td>
<td>Acute myeloid leukemia (AML) 2nd line (P3) (TLR:1H CY2017)</td>
<td>Orphan Drug Designation by the FDA and EMA, Fast Track Status by the FDA, Anticipating effectiveness to patients with FLT3-ITD patients to whom midostaurin doesn't show efficacy, First-line study in preparation</td>
</tr>
<tr>
<td>Tivantinib</td>
<td>~30.0 Bn JPY</td>
<td>Hepatocellular carcinoma (HCC)(P3) (TLR:1H CY2017)</td>
<td>Orphan Drug Designation by the FDA and EMA, Refractory HCC, Anticipating high effectiveness by stratification of patients</td>
</tr>
<tr>
<td>Pexidartinib</td>
<td>~100.0 Bn JPY</td>
<td>Tenosynovial giant cell tumor (TGCT)(P3) (TLR:1H CY2018) Solid tumor(P1/2a) (TLR:2H CY2019)</td>
<td>Orphan Drug Designation by the FDA and EMA, Breakthrough Therapy designation by FDA, Combination therapy with Merck’s anti-PD-1 antibody</td>
</tr>
<tr>
<td>Patritumab</td>
<td>~50.0 Bn JPY</td>
<td>Non-small cell lung cancer (NSCLC)(P2/3) (TLR:2H CY2018) Head and Neck cancer (P2)</td>
<td>Anticipating high effectiveness in specific group of patients selected by biomarker, Have obtained good results in P1b study, Data to be published at ECHNO in April 2016</td>
</tr>
</tbody>
</table>

TLR: anticipated Top Line Result
<table>
<thead>
<tr>
<th>Drug Code</th>
<th>Condition</th>
<th>Key Points</th>
</tr>
</thead>
</table>
| DS-8201 (HER2-ADC) | Solid tumor (P1) | • Anticipating effectiveness to patients resistant to treatment by Herceptin or Kadcyla  
• Applied DS proprietary ADC* technology  
• Target: obtaining of phase 1 results in FY2017  
*Antibody Drug Conjugate |
| DS-3201 (EZH1/2) | Non-Hodgkin's lymphoma (incl. adult T-cell leukemia) (P1) | • Targeted epigenetics**  
• Expecting permanent cure of hematological cancer by eradication of “cancer stem cell”  
• FIC as an EZH 1/2 dual inhibitor  
• Anticipating More potent as compared to EZH2 inhibitor  
• Target: completion of phase 1 study in FY2018  
**Chemical modification of DNA or histone leading to acquired change in gene expression without modification of DNA sequence |
| DS-3032 (MDM2) | Solid tumor Hematologic tumor(P1) | • Anticipating high effectiveness to cancer with MDM2 gene amplification/Wt p53  
• FIC  
• Based on the phase 1 study in the US suggesting effectiveness in patients with liposarcoma (LPS), LPS is selected as a potential indication for further development, which is under consideration. |
| DS-6051 (NTRK/ROS1) | Solid Tumor (Lung cancer) | • ROS1 fusion is one of the major diver mutations observed in lung cancer etc.  
• Phase 1 study is planned to complete in FY2017 (US/JP)  
• Partial response is observed in a patient in US P1 study. Interim analysis of efficacy and safety to be presented at AACR in April 2016.  
• Utilizing SCRUM-Japan*** for patient selection in Japan  
***SCRUM-Japan: National project led by National Cancer Center Japan to screen oncogenic abnormality of cancer patients in order to provide the best-fit medicines to them |
Enrich Pipeline by Acquisition of External Assets

- Enhanced portfolio through M&A
  - U3 pharma (patritumab, U3-1784 etc.)
  - Plexxikon (Zelboraf, pexidartinib etc.)
  - Ambit (quizartinib etc.)

- Alliance: collaboration in R&D or sales
  - ArQule (tivantinib)

- Accelerate alliance opportunities or product acquisition
- Prioritize oncology as an investment target for business development
Accelerate Oncology R&D by new R&D Organization

<Global Structure>
Regional Value Products

Strategy 3

Grow as No.1 company in Japan
Comprehensive Contribution to Medical Needs in Japan with 4 Business Segments

Tailoring various medical/health needs in Japan with 4 business segments

Innovative Pharmaceuticals

- Continued provision of innovative pharmaceuticals
- Aim to be trusted as medical partner in local healthcare

Vaccines

No.1 Vaccines company
- Continue to introduce new products
- Secure market share through first entry

Generic Pharmaceuticals

No.1 Gx company with innovation background
- Secure market share through steady launch of day 1 Gxs
- Strengthen AG lineup
- Step up coordination with partners in Japan and overseas

OTC Drugs

- Expand OTC drug business centered on LOXONIN S and Lulu
- Grow by expanding channels such as Im’s Internet sales, etc.

Prevention

Rx-to-OTC switch

Therapy

Self-medication

Decreasing birthrate and aging Society
Realize sustainable growth by leveraging No.1 sales capabilities of leading company in Japan

- Continuous launch & sales growth of own products
- Growth of Japan Business
- No.1 market share
- Top class sales capabilities in quantity and quality
- Fine-tuned sales capabilities
- No.1 evaluation
- Acquire valuable new products
- Sales growth of acquired products
Grow Major Products in Japan

Maintain growth by existing products and additional indications

Product strategies

- **Nexium (anti-ulcer: Proton Pump Inhibitor)**
  Maintain No. 1 share by establishing position as “first choice” drug for GERD* treatment

- **Memary (treatment for Alzheimer’s Disease)**
  Standardize combination therapy with ChE** inhibitor for the treatment of moderate-to-severe AD*** by provision of clinical evidence

- **Pralia (treatment for osteoporosis)**
  Expand market penetration by promoting high evaluation received by guideline
  Further growth by additional indication of rheumatoid arthritis

- **Ranmark (treatment for bone metastasis)**
  Maintain position as standard of care for treating bone metastasis of cancer
  Further growth by additional indication of breast cancer

- **Efient (antiplatelet)**
  Maintain dominating No. 1 share in heart area by promoting dosage ideal for Japanese
  Lead next generation of antiplatelet treatment in Japan by additional indication of brain area

- **Teneria (treatment for type 2 diabetes)**
  Appeal efficacy and ease of use for elderly people and patients with renal impairment to aim for first-line treatment for diabetes and expand market share
  Red: additional indication (Planned)

*GERD: Gastroesophageal Reflux Disease
**ChE: Cholinesterase
***AD: Alzheimer’s disease

Total of 6 products in right column (excl. Lixiana), Including the impact of mandated price revisions
New Products and Additional Indications

Seamless launch of new products and additional indications

**New product**
- Lacosamide (Epilepsy)
- VN-100 (Seasonal flu vaccine)

**New product**
- Hydromorphone (Cancer pain)
- Etanercept BS (Rheumatoid arthritis)
- VN-0107/MEDI3250 (Seasonal flu vaccine as a nasal spray)

**New product**
- Mirogabalin (DPNP, PHN)*

**New product**
- VN-0102 (Measles-Mumps-Rubella vaccine)

**New product**
- CS-3150 (Hypertension)
- Quizartinib (Acute myeloid leukemia)
- VN-0105 (DPT-IPV/Hib vaccine)

**Additional indication**
- Prasugrel (Ischemic stroke)
- Denosumab (Rheumatoid arthritis)

**Additional indication**
- Denosumab (Breast cancer adjuvant)

*DPNP: Diabetic peripheral neuropathic pain
PHN: Postherpetic neuralgia
Establish Area Marketing Structure for Integrated Community Care System

Aim to be trusted as medical partner in medical community

Enhance the necessary role and system in accordance with integrated community medical system on the basis of medical community vision

Medical community area

Enhance area marketing structure
- Align with segmentation of medical function
- Engage with home doctor
- Engage with medical association and local government
- Engage with corporation of community medical collaboration

Corporation of community medical collaboration

Set up staff supporting community medical collaboration

Daiichi Sankyo
Reorganization to strengthen the structure (April 2016)
Regional Value Products

Strategy 4

Expand US Businesses
Expand US businesses

◆ Business expansion in Pain Franchise (DSI*)
  ➢ Movantik
  ➢ CL-108
  ➢ Mirogabalin

* DSI: Daiichi Sankyo Inc.

◆ Growth of Luitpold Business
  ➢ Iron Franchise
  ➢ Generic Injectable
U.S. Pain Market Holds Great Opportunity

Large, Growing Market with Diverse Segments

U.S. Pain Market Gross Sales (US$ Billion)

2015: $28 Billion

‘07-’15 CAGR 6.6%

- Opioids
- Others

330~ Million TRx

* Immediate-Release Opioid, ** Extended-Release Opioid
† Pain management use only

Movantik

◆ First once-daily oral product FDA approved for the treatment of opioid-induced constipation (OIC) for adults with chronic non-cancer pain
◆ Co-promotion with AstraZeneca from FY15 and 1.3 billion yen revenue up to December 2015
◆ While the reported occurrence of OIC varies, it affected roughly 40% of patients in clinical trials who were taking opioids for chronic pain\(^1\)

CL-108

◆ Novel, bi-layered tablet containing hydrocodone, acetaminophen and promethazine to treat moderate to severe pain and prevent or reduce opioid-induced nausea and vomiting (OINV)

◆ Hydrocodone/Acetaminophen (HC/APAP) is the standard of care for acute pain after injury & surgery and prescribed for 53.2 Mn patients in the U.S.\(^1\)

◆ Reports in the literature suggest approximately 40% of patients experience OINV, and the incidence may be higher in clinical practice 2~6

◆ Met primary endpoints in two pivotal Ph3 studies
  ◆ Similar efficacy and lower incidence of OINV vs HC/APAP alone in first pivotal Ph3 study*
  ◆ Significant pain relief vs placebo and prevention of OINV vs HC/APAP (both p<0.001)**
  * (N=466 Molar Extraction Patients in the U.S.)
  ** (N=550 Bunionectomy Patients in the U.S.)

---

Mirogabalin

◆ If approved, mirogabalin could provide a superior, more convenient and safe therapeutic option for patients with pain associated with fibromyalgia
◆ The α2δ-ligand Market as large as 64MM Prescriptions in 2015 ¹
◆ Ph3 control drug: pregabalin - U.S. Net sales reached $2.7 Billion in 2015 ²
◆ ~57% drop treatment of α2δ-ligand at 12 months (unsatisfied with its efficacy) ³
◆ Top line results anticipated 1H CY2017

1. Symphony Health Solutions, PHAST Prescription Monthly, 2015
2. Pfizer Quarterly Corporate Performance – Fourth Quarter 2015
Rapid Growth in Pain Franchise

> 100 Bn JPY business in FY2020

KSF & main tactics

- **Movantik**
  - Raise awareness of burden of OIC
  - Inspire a conversation about OIC
  - Deliver affordable access

- **CL-108: Targeted launch in FY 2017**
  - Raise HCPs’ OINV awareness
  - Engage the medical community

- **Mirogabalin :Targeted launch in FY 2019**
  - Differentiate from pregabalin based on Ph3 results
Realize rapid and sustainable growth with Iron Franchise and Generic injectable franchise

**IRON FRANCHISE**

- **Build Injectafer into our flagship product & market leader (CAGR 20-30%)**
  - Execute LCMs
  - Expand Sales Team coverage to other specialties that treat IDA such as Cardiology, OBGYN, etc.
  - Gain Market share >40% in Hem/Onc segment

**GENERIC INJECTABLE FRANCHISE**

- **Maximize / expand existing portfolio**
  - Focus on high market value products, e.g. anti-cancer drugs

- **Expand Manufacturing capabilities as a top 4 supplier in US Generic Injectable Market**
  - Shirley plant: Upgrade existing manufacturing infrastructure
  - New Albany plant: Consolidate operation & capacity expansion
  - Hilliard plant: Maximize space use & capacity expansion
Value for Pipeline

Strategy 5

Continuously Generate Innovative Medicine

Changing SOC
Continuous Generate Innovative Medicine
Changing SOC

◆ Create new drugs in Oncology/New Horizon area
  ➢ Target therapeutic area
  ➢ Transform research organization to bioventure model

◆ Realize clinical application of innovative technology
  ➢ Advancement of technologies
  ➢ Nucleic acid drug: develop drugs for Duchenne muscular dystrophy
  ➢ Cell therapy: explore seeds utilizing alliance and move them forward to commercialization quickly
Target Therapeutic Area

**Oncology** (incl. Immune Oncology)
Generate molecular target drugs with potential to cure or prolong life significantly by mono therapy or combination

**Primary Focused Area**

**New horizon Area**

**Pain**
- Generate drugs for pain complementing MOA of current development pipeline

**CNS* disease**
- Generate drugs for neurodegenerative disease through collaborative research with UCSF

**Heart • Kidney disease**
- Utilize accumulated knowledge
- Utilize collaborative research with Sanford Burnham

**Rare diseases**
- Optimize modality, such as nucleic acid, antibody and small molecule

Partnering, Open innovation Translational Research

Continuously generate innovative medicine changing SOC
Bioventure model

- Small unit with both functions of pharmacologists and medicinal chemists (biologics)
- **Empowered decision making** for research theme
- **Resource allocation in accordance with outputs (results)**

- **Activation of innovative mind**
- **Quick decision making**

**Acceleration of research & improvement of productivity**
Realize Clinical Application of Innovative Technology: Advancement of Technologies

Progress in technology

Business value opportunities

1st wave
- naked antibody

2nd wave
- ADCC*
- ADC**
- Bispecific
- Protein scaffold

3rd wave
- Peptide
- Nucleic acid
- Cell therapy etc.

Next stage for clinical entry

DS-8201
DS-8895
DS-5573

Started phase 1 study

DS-5141

DS-5141

DS-5573

* ADCC: Antibody Dependent Cellular Cytotoxicity
**ADC: Antibody Drug Conjugate
Realize Clinical Application of Innovative Technology: Nucleic Acid Drug

**DS-5141: Duchenne muscular dystrophy**
- Achieved the first dosing in the First-in-human phase 1/2 study (Feb. 2016)
- Targeted manufacture and sales approval by 2020 in Japan

[application of DS proprietary technology and risk-hedge mechanism]

*ODTI: Orphan Disease Treatment Institute Co., Ltd.*
**INCJ: The Innovation Network Corporation of Japan**
***MUC: Mitsubishi UFJ Capital Co., Ltd.
Establish Cell Therapy Laboratories

- Expand initiatives for cell therapy across the DS Group
- Pursue synergy between DS and Asubio through integration of each organization’s advantages, such as biologic technologies, iPS, and stem cell research

Explore seeds utilizing alliances and move them forward to commercialization quickly

- Enter cell therapy business quickly by expansion of alliance and in-licensing activities
- Establish pipelines by open innovation from mid-term or long-term viewpoints
  - Find seeds from academia using TaNeDS or OiDE fund
- Target therapeutic areas with high unmet medical needs, such as heart disease or neurological disease, and plan to clinical entry during 5-Year Business Plan

→ Collaborative research on-going with several academia
Highly Efficient Management

Strategy 6

Enhance Profit Generation
Enhance Profit Generation

Realize Process Excellence

- Major measures conducted by FY2015
  - Sale of Akita plant
  - Restructuring in Japan
    - Restructuring in US
    - Restructuring in EU
  - Restructuring in R&D

Profit generation

- Cost of Sales
- SG&A expenses
- R&D expenses

Optimization of manufacturing systems globally

To realize during 5YBP

- Further enhancement of procurement
- Further cost reductions and streamlining
◆ Challenge 1: Grow beyond FY2017 LOE
  ➢ Measures of Revenue Recovery
  ➢ Measures of Profit Generation
◆ Challenge 2: Establish Foundation of Sustainable Growth
  ➢ FY2020 Targets and Business Strategy
  ➢ Investment for Future Growth and Shareholder Returns
  ➢ CSR and Corporate Governance
◆ Conclusion
Enhance Cash Flow Generation

Increase in free cash flow before R&D expenses

Streamlining of assets

Current assets
- Shorten CCC*

Fixed assets
- Liquidate non-core assets
- Optimize capital expenditure

Securities
- Reduce Cross-Shareholding shares

*CCC: Cash conversion cycle
Investment for Future Growth and Shareholder Returns

Prioritize growth investments while enhancing shareholder returns

- **End of FY2015 Cash-on-hand**: Approx. 700.0 Bn JPY
- **Approx. 2,200.0 Bn JPY**
- **5-year aggregated cash allocation funds**
- **Streamlining of assets**
- **Free Cash Flow before R&D expenses**
  (=Profit before R&D/depreciation/amortization)
- **R&D expenses**: 900.0 Bn JPY
- **Shareholder returns**: (Dividends Acquisition of own shares)
- **Business Development investments**: 500.0 Bn JPY
- **Investment for future growth**

(allocation image)
Investment for future growth

R&D expenses
Approx. 900.0 Bn JPY

Business development investments
Approx. 500.0 Bn JPY

Most prioritized investment: Oncology

Invest others according to our below strategies

<Strategy 1>
Grow Edoxaban

<Strategy 3>
Grow as No.1 company in Japan

<Strategy 4>
Expand US businesses

<Strategy 5>
Continuously generate innovative medicine changing SOC
Shareholder Returns Policy during 5YBP

◆ Total return ratio* : 100% or more

Total return ratio = (Dividends + Total acquisition costs of own shares) / Profit attributable to owners of the company

◆ Annual ordinary dividends : more than 70 JPY

◆ Flexible acquisition of own shares

*Statement on total return ratio

The total shareholder return ratio may be different from the numbers Daiichi Sankyo forecasts due to factors involving strategic investments, including R&D costs and business development investments, material changes of the business environment surrounding Daiichi Sankyo or business performance of Daiichi Sankyo, legal or compliance issues such as insider trading regulations, or other facts or circumstances. The increase of cash flow related to the total shareholder return ratio may not be realized as expected in this material due to a variety of circumstances, such as the market penetration of generic drugs, delay or cancelation of approvals for new drugs, payment of damages or compensation in connection with litigation or other legal proceedings.
Challenge 1: Grow beyond FY2017 LOE
- Measures of Revenue Recovery
- Measures of Profit Generation

Challenge 2: Establish Foundation of Sustainable Growth
- FY2020 Targets and Business Strategy
- Investment for Future Growth and Shareholder Returns
- CSR and Corporate Governance

Conclusion
CSR

◆ Promote compliance management
  - Dissemination of global compliance policy, such as Daiichi Sankyo Group Individual Conduct Principles

◆ Facilitate mutual growth of employees and Company
  - Human resources development to realize value creation and secure competitive advantage through our corporate values of Innovation, Integrity, Accountability and respect for diversity

◆ Enhance communication
  - Effective disclosure and performance improvement of CSR & ESG

◆ Promote environmental management
  - Reducing environment impacts and risks, and addressing climate change (FY2020 CO2 emissions target: 5.6% reduction from FY2015)

◆ Access to healthcare
  - Promoting R&D for Intractable disease, Orphan disease and Global Health
  - Mobile healthcare field clinics, Healthcare professionals development, Health and hygiene training to the local in the regions face a lack of medical infrastructure
Corporate Governance

Current Status

- Four out of ten members of the Board are independent outside directors
- A Nomination Committee and a Compensation Committee, each of which is chaired by a outside director, are established voluntarily
- An Audit & Supervisory Board system is adopted. The Audit & Supervisory Board consists of four members, including two outside members
- Specific criteria for the judgment of independence of outside members of the Board and the Audit & Supervisory Board are disclosed
- The Corporate Governance Code is fully complied

Continuous improvement of Corporate Governance structure

Enhance Shareholders’ Value
Challenge 1: Grow beyond FY2017 LOE
- Measures of Revenue Recovery
- Measures of Profit Generation

Challenge 2: Establish Foundation of Sustainable Growth
- FY2020 Targets and Business Strategy
- Investment for Future Growth and Shareholder Returns
- CSR and Corporate Governance

Conclusion
FY2020 Targets

<table>
<thead>
<tr>
<th></th>
<th>FY2015 (Forecast)</th>
<th>FY2017 (Target)</th>
<th>FY2020 (Target)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue (Bn JPY)</td>
<td>980.0</td>
<td>940.0</td>
<td>1,100.0</td>
</tr>
<tr>
<td>Operating Profit (Bn JPY)</td>
<td>130.0</td>
<td>100.0</td>
<td>165.0</td>
</tr>
</tbody>
</table>

- Increase value of late-stage pipeline
  3 - 5 products launched within the next 5 years with peak-sales of more than 100.0 Bn JPY each

- ROE: 8% or more (FY2020)

- Total return ratio: 100% or more (during 5YBP)

- Annual ordinary dividends: more than 70 JPY (during 5YBP)

Assumption: Exchange rate of 1USD=120JPY, 1EUR=130JPY
Global Pharma Innovator with Competitive Advantage in Oncology

2025 Vision
- To have Specialty area business centered on Oncology business as the core business
- To have enriched regional value products aligned with regional market
- To have innovative products and pipeline changing SOC
- To realize shareholders’ value through highly efficient management

2016-2020 5-Year Business Plan
Transformation toward 2025 Vision

Until 2015
- CVM area
- PCP focus
- Global products
- In-house
- Sales volume
5-Year Business Plan
(FY2016 - FY2020)

DS Transformation
—A Bridge to Tomorrow
Reference
# Major R&D Pipeline

<table>
<thead>
<tr>
<th>Therapeutic area</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>- DS-3032 (US/JP) (MDM2 inhibitor)</td>
<td>- Patritumab (US/EU) (U3-1287 / Anti-HER3 antibody)</td>
<td>- Tivantinib (US/EU) (ARG 197 / HCC / MET inhibitor)</td>
<td>- Edoxaban (ASCA etc.) (DU-176b / AF / oral factor Xa inhibitor)</td>
</tr>
<tr>
<td></td>
<td>- PLX7486 (US) (FMS / TRK inhibitor)</td>
<td>- Pexidartinib (US) (PLX3397 / CSF-1R/KIT/FLT3-ITD inhibitor)</td>
<td>- Denosumab (JP) (AMG 162 / Breast cancer adjuvant / Anti-RANKL antibody)</td>
<td>- Edoxaban (ASCA etc.) (DU-176b / VTE / oral factor Xa inhibitor)</td>
</tr>
<tr>
<td></td>
<td>- PLX8394 (US) (BRAF inhibitor)</td>
<td></td>
<td>- Nimotuzumab (JP) (DE-766 / Gastric cancer / Anti-EGFR antibody)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- DS-6051 (US) (NTRK/ROS1 inhibitor)</td>
<td></td>
<td>- Vemurafenib (US/EU) (PLX4032 / Melanoma Adjuvant / BRAF inhibitor)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- PLX9486 (US) (KIT inhibitor)</td>
<td></td>
<td>- Quizartinib (US/EU/Asia) (AC220 / AML / FLT3-ITD inhibitor)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DS-3201 (JP)</strong> (EZH1/2 inhibitor)</td>
<td></td>
<td>- Pexidartinib (US/EU) (PLX3397/TGCT / CSF-1R/KIT/FLT3-ITD inhibitor)</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular-Metabolics</strong></td>
<td>- DS-1040 (Acute ischemic stroke / TAFIa inhibitor)</td>
<td>- CS-3150 (JP) (Hypertension - DM nephropathy / MR antagonist)</td>
<td>- Prasugrel (JP) (CS-747 / Ischemic stroke / Anti-platelet agent)</td>
<td>- Intradermal Seasonal Influenza Vaccine (JP) (VN-100 / prefilled i.d. vaccine for seasonal flu)</td>
</tr>
<tr>
<td></td>
<td>- DS-2330 (Hyperphosphatemia)</td>
<td>- DS-8500 (JP/US) (Diabetes / GPR119 agonist)</td>
<td></td>
<td>- VN-101 (JP) (Cell-culture HSN1 Influenza vaccine)</td>
</tr>
<tr>
<td></td>
<td>- DS-9231/TS23 (Thrombosis / a2-P1 inactivating antibody)</td>
<td>- DS-9001 (Dyslipidemia / Anti-PCSK9 Anticalin-Albumod)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td>- DS-1971 (Chronic pain)</td>
<td>- Laninamivir (US/EU) (CS-8958 / Anti-influenza / out-licensing with Biota)</td>
<td>- Mirogabalin (US/EU) (DS-5565 / Fibromyalgia / α2δ ligand)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- DS-1501 (Osteoporosis / Anti-Siglec-15 antibody)</td>
<td></td>
<td>- Mirogabalin (JP/Asia) (DS-5565 / DPNP/ α2δ ligand)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- DS-7080 (US) (AMD / Angiogenesis inhibitor)</td>
<td></td>
<td>- Mirogabalin (JP/Asia) (DS-5565 / PHN / α2δ ligand)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- DS-2969 (Clostridium difficile infection /GyrB inhibitor)</td>
<td></td>
<td>- Denosumab (JP) (AMG 162 / Rheumatoid arthritis / Anti-RANKL anti-body)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DS-5141 (JP)</strong> (DMD / ENA oligonucleotide)</td>
<td></td>
<td>- Hydromorphone (JP) (DS-7113 / Cancer pain / Opioid μ-receptor regulator)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- VN-0102/JVC-001 (JP) (MMR vaccine)</td>
<td></td>
<td>- CHS-0214 (JP) (Etanercept BS / Rheumatoid arthritis / TNFα inhibitor)</td>
<td></td>
</tr>
</tbody>
</table>

As of January 2016. Red: Phase 1 entry was announced after the FY2015 Q3 financial announcement on January 29, 2016.
Targeted Launch during 5YBP

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Japan</td>
<td>Prasugrel CVA</td>
<td>Hydromorphone Cancer pain</td>
<td>Denosumab RA</td>
<td>Mirogabalin DPNP&amp;PHN</td>
<td>CS-3150 Hypertension</td>
</tr>
<tr>
<td></td>
<td>Lacosamide Epilepsy</td>
<td>Etanercept BS RA</td>
<td>VN-100 Seasonal flu</td>
<td>VN-0107 Nasal spray flu vaccine</td>
<td>VN-0105 DTP-IPV/Hib</td>
</tr>
<tr>
<td></td>
<td>VN-0105 DTP-IPV/Hib</td>
<td>VN-0102 MMR</td>
<td>Tivantinib HCC</td>
<td>Pexidartinib TGCT</td>
<td>Pexidartinib TGCT</td>
</tr>
<tr>
<td></td>
<td>CL-108 Acute pain</td>
<td>CL-108 Acute pain</td>
<td>Tivantinib HCC</td>
<td>Tivantinib HCC</td>
<td>Patritumab NSCLC</td>
</tr>
<tr>
<td></td>
<td>Tivantinib AML 2nd</td>
<td>Tivantinib AML 2nd</td>
<td>Pexidartinib TGCT</td>
<td>Pexidartinib TGCT</td>
<td>Patritumab NSCLC</td>
</tr>
<tr>
<td></td>
<td>Hydromorphone Cancer pain</td>
<td>Hydromorphone Cancer pain</td>
<td>Quizartinib TGCT</td>
<td>Quizartinib TGCT</td>
<td>Denosumab BC-adjuvant</td>
</tr>
<tr>
<td></td>
<td>VN-100 Seasonal flu</td>
<td>VN-0107 Nasal spray flu vaccine</td>
<td>Mirogabalin FM</td>
<td>Mirogabalin FM</td>
<td>VN-0105 DTP-IPV/Hib</td>
</tr>
<tr>
<td></td>
<td>Tivantinib AML 2nd</td>
<td>Tivantinib AML 2nd</td>
<td>Patritumab NSCLC</td>
<td>Patritumab NSCLC</td>
<td>VN-0102 MMR</td>
</tr>
<tr>
<td></td>
<td>Hydromorphone Cancer pain</td>
<td>Hydromorphone Cancer pain</td>
<td>Pexidartinib TGCT</td>
<td>Pexidartinib TGCT</td>
<td>Pexidartinib TGCT</td>
</tr>
<tr>
<td></td>
<td>VN-100 Seasonal flu</td>
<td>VN-0107 Nasal spray flu vaccine</td>
<td>Mirogabalin FM</td>
<td>Mirogabalin FM</td>
<td>VN-0105 DTP-IPV/Hib</td>
</tr>
<tr>
<td></td>
<td>Tivantinib AML 2nd</td>
<td>Tivantinib AML 2nd</td>
<td>Patritumab NSCLC</td>
<td>Patritumab NSCLC</td>
<td>VN-0102 MMR</td>
</tr>
<tr>
<td></td>
<td>Hydromorphone Cancer pain</td>
<td>Hydromorphone Cancer pain</td>
<td>Pexidartinib TGCT</td>
<td>Pexidartinib TGCT</td>
<td>Pexidartinib TGCT</td>
</tr>
<tr>
<td></td>
<td>VN-100 Seasonal flu</td>
<td>VN-0107 Nasal spray flu vaccine</td>
<td>Mirogabalin FM</td>
<td>Mirogabalin FM</td>
<td>VN-0105 DTP-IPV/Hib</td>
</tr>
<tr>
<td></td>
<td>Tivantinib AML 2nd</td>
<td>Tivantinib AML 2nd</td>
<td>Patritumab NSCLC</td>
<td>Patritumab NSCLC</td>
<td>VN-0102 MMR</td>
</tr>
</tbody>
</table>

Specialty

PCP area

Vaccine

74
Daiichi Sankyo Co., Ltd.
Corporate Communications Department

TEL: +81-3-6225-1126